Active Ingredient History

  • Now
Nisoldipine is a 1,4-dihydropyridine derivative with an outstanding vascular selectivity. As a specific calcium antagonist, it shortens the action potential and causes electromechanical uncoupling in ventricular myocardium. However, this effect, resulting in a negative inotropic action, appears at 100–1000 times higher concentrations of nisoldipine in comparison with its inhibition of calcium-dependent vascular contractions. Detailed analyses of pharmacological effects revealed additional properties such as enhancement of sodium excretion, an interaction with the reninangiotensin-aldosterone system and a protective effect against acute renal ischaemia, that may contribute to its therapeutic efficacy. Nisoldipine was developed at Bayer then licensed to Zeneca and marketed in the United States as SULAR. SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. The mechanism of the therapeutic effect of nisoldipine is complex. It involves a decrease of the total peripheral vascular resistance (reduction of afterload) and an increase in coronary blood flow. Moreover, nisoldipine obviously normalises the impaired volume homoeostasis by improving renal function and thus reduces the need for activation of the ANP system. In the advanced stages of hypertension, nisoldipine prevents deleterious calcium overload and the resulting tissue damage.   NCATS

  • SMILES: COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC=C2[N+]([O-])=O)C(=O)OCC(C)C
  • Mol. Mass: 388.4144
  • ALogP: 3.2
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$0.6737 - $23.1884
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bay k-5552 | bay-k-5552 | isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | nisoldipin | nisoldipina | nisoldipine | nisoldipino | nisoldipinum | sular | syscor mr 10 | syscor mr 20 | syscor mr 30 | zadipina


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue